Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CFI-400945 and Durvalumab in Advanced/Metastatic TNBC
NCT04176848Phase 2Active, not recruiting
- Sponsor
- Canadian Cancer Trials Group
- Start
- Aug 2020
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ocifisertib in triple-negative breast cancer (TNBC), sponsored by Canadian Cancer Trials Group. Started Aug 2020; status: active, not recruiting.
02
Drugs
ocifisertib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04176848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04176848.